Sudden cardiac arrest and coexisting mitral valve prolapse: a case report and literature review by Ahmed, M et al.
This work is licensed under a Creative Commons 
Attribution-NonCommercial-NoDerivs 4.0  
International License.
© 2016 The authors www.echorespract.com
 Published by Bioscientifica Ltd
Abstract
The aetiology of sudden cardiac arrest can often be identified to underlying cardiac 
pathology. Mitral valve prolapse is a relatively common valvular pathology with 
symptoms manifesting with increasing severity of mitral regurgitation (MR). It is 
unusual for severe MR to be present without symptoms, and there is growing evidence 
that this subset of patients may be at increased risk of sudden cardiac arrest or death. 
The difficulty lies in identifying those patients at risk and applying measures that are 
appropriate to halting progression to cardiac arrest. This article examines the association 
of mitral valve prolapse with cardiac arrests, the underlying pathophysiological process 
and the strategies for identifying those at risk.
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A 45-year-old male had a sudden collapse at home, wit-
nessed by their partner who started bystander cardiopul-
monary resuscitation (CPR). The initial observed cardiac 
rhythm was pulseless ventricular tachycardia on arrival of 
the emergency medical services. A direct current shock was 
delivered resulting in asystole. The patient underwent a fur-
ther 10 min of CPR prior to the return of spontaneous cir-
culation, during which time endotracheal intubation and 
positive pressure ventilation were commenced. The total 
low-flow time was between 20 and 30 min. The patient was 
transported by air ambulance to a tertiary cardiac arrest 
centre. The patient was transferred to the accident and 
emergency department where intravenous sedation was 
started and maintained. The body temperature was mea-
sured at 34.9°C. Initial blood investigations were as fol-
lows: troponin I 350 ng/mL, C-reactive protein <4 mg/mL, 
leucocyte count 18  × 103/µL, sodium 140 mmol/L, potas-
sium 3.1 mmol/L, urea 6.6 mmol/L, creatinine 66 µmol/L 
and glucose 12 mmol/L. Initial arterial blood gas sampling 
demonstrated a pH 7.31, PaCO2 6.41 kPa, PaO2 62.9 kPa, 
base excess −1.7 and lactate 3.0 mmol/L. The ECG showed 
sinus rhythm, there were no signs of ischaemia and it 
fulfilled electrical criteria for left ventricular hypertrophy 
(Fig. 1). A chest X-ray showed the presence of an endotra-
cheal tube, but it was otherwise unremarkable. A CT scan 
of the head was obtained which was reported as normal.
Collateral history determined that the patient had no 
significant co-morbidities and that the patient was healthy 
prior to the sudden cardiac event. A bedside transthoracic 
echocardiogram was obtained (Videos 1 and  2). This 
reported a thickened and prolapsing anterior mitral valve 
leaflet with associated severe mitral regurgitation (MR). 
The left ventricular ejection fraction was inappropriately 
normal, but not hyperdynamic; although impaired when 
the severe MR was taken into account. There was no 
evidence of a systolic regional wall motion abnormality. 
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On this evidence, the patient was treated empirically 
with vancomycin and gentamicin for suspected infective 
endocarditis and transferred to the intensive care unit.
Video 1
Parasternal long-axis TTE zoomed in on the mitral valve 
showing a prolapsing anterior leaflet with evidence of 
cordal rupture. View Video 1 at http://movie-usa.glen-
coesoftware.com/video/10.1530/ERP-15-0020/video-1.
Video 2 
Apical 2/3 chamber TTE zoomed in on the mitral valve show-
ing the anterior leaflet. View Video 2 at http://movie-usa.
glencoesoftware.com/video/10.1530/ERP-15-0020/video-2.
In line with current protocols, the patient’s tempera-
ture was allowed to increase to 36°C and maintained at 
this level for the first 24 h. An infusion of norepineph-
rine was commenced to maintain a mean arterial blood 
pressure greater than 65 mmHg. A transoesophageal echo-
cardiography (TOE) was performed 12 h after admission 
(Videos 3 and 4). This confirmed a flail A2 segment sec-
ondary to chordal rupture with evidence of myxomatous 
degeneration. The mitral annulus was dilated at 5.2 cm. 
No vegetations were observed on the mitral valve. Doppler 
interrogation confirmed the presence of severe MR. The 
left ventricle (LV) diastolic dimension was 7.2 cm, the 
systolic dimension was 5.3 cm and the ejection fraction 
(Simpson’s biplane) was 58%. A coronary angiogram was 
performed and showed normal unobstructed coronary 
arteries. Empirical antibiotic therapy for bacterial endo-
carditis was discontinued following TOE.
Video 3 
TOE showing a truncated commissural view with a 




Initial ECG on admission to hospital.
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Video 4 
TOE showing the 2D appearance from Video 3 with colour 
flow Doppler added. There is regurgitation through the 
centre of the valve corresponding to A2. This is difficult to 
visualise due to the hyperdynamic ventricular function. 
View Video 4 at http://movie-usa.glencoesoftware.com/
video/10.1530/ERP-15-0020/video-4.
Following antibiotic therapy for hospital-acquired 
pneumonia, mechanical ventilation was successfully 
weaned and the trachea was successfully extubated 
1 week after admission. Although the patient experienced 
an initial deficit in short-term memory function, they 
continue to make a good neurological recovery. Prior 
to hospital discharge, a single lead implantable cardiac 
defibrillator was inserted given the significant risk of 
further malignant ventricular rhythms. Three weeks later, 
a cardiac magnetic resonance imaging scan was performed, 
which showed a severely dilated LV with mild impairment 
of left ventricular function and severe MR. Further inquiry 
revealed no family history of sudden cardiac death, 
cardiac disease or connective tissue disorders. Genetic 
testing is yet to be performed. The patient was discharged 
home from hospital 3 weeks after admission with referral 
for cardiac surgery to repair the mitral valve prolapse.
Review of sudden cardiac arrest with 
coexisting mitral valve prolapse
Introduction
We report a case of out-of-hospital cardiac arrest 
(OOHCA) secondary to ventricular tachycardia (VT) likely 
related to mitral valve prolapse (MVP) and severe mitral 
regurgitation (MR).
Sudden cardiac death (SCD) is an unexpected natural 
death from a cardiac cause within a short time period (1). 
In most epidemiologic studies, this short period is defined 
within 1 h from the onset of symptoms. UK data show 
that an incidence of SCD is 100,000 adults per year (2). In 
the USA, it accounts for about 300,000 cases annually rep-
resenting about 50% of mortality from cardiac causes (3). 
The overall incidence is about 50 – 100:100,000 people per 
year. On average, the survival with good neurologic recov-
ery after OOHCA is about 5 – 10% (4). Due to the short 
time period from the onset of symptoms to arrest, identi-
fication of the high-risk population and prevention is the 
most effective strategy. Causes of SCD include coronary 
artery disease, cardiomyopathies, structural heart disease 
and primary electrophysiologic abnormalities. In some 
patients, the cause remains unclear, and hence, the term 
‘idiopathic ventricular fibrillation’ is used (4).
Definition
MVP is defined as displacement of mitral leaflet tissue 
into the left atrium past the mitral annular plane during 
systole (5). It was first described by Barlow in the 1960s as 
an auscultatory and cine-angiocardiographic phenomenon, 
prior to the availability of diagnostic echocardiography 
(6, 7, 8). Advances in echocardiography (e.g. transoesoph-
ageal echocardiography (TOE) and three-dimensional 
imaging) have made it possible for accurate diagnosis and 
quantification of MR (9).
The role of echocardiography in MVP
Echocardiography can be used for diagnosis, surveillance 
and assessment of interventions in MVP. Carpentier’s 
functional classification of MR described MVP (Type II 
classification) as an abnormality of leaflet motion, where 
one or several components of the valve protrude into 
the left atrium (LA) during ventricular systole (10). Two-
dimensional (2D) echocardiography can be used to divide 
MVP into classical and non-classical criteria for diagnosis 
(11). Classical MVP describes > 2 mm displacement of the 
mitral valve leaflets into the LA in long-axis view during 
ventricular systole, with a leaflet thickness of ≥5 mm. Non-
classical MVP describes >2 mm leaflet displacement with a 
leaflet thickness of <5 mm.
Classical MVP will have either a symmetrical or an 
asymmetrical point of coaptation. Both leaflet tips meet at 
the same point on the mitral valve annulus in symmetri-
cal MVP. Asymmetrical coaptation results in one leaflet 
being displaced towards the LA in relation to the other 
leaflet. Asymmetrical coaptation is more likely to deterio-
rate and develop flail prolapse and result in greater sever-
ity of MR. Flail segment or prolapse describes the presence 
of leaflet tips that turn outwards and point into the LA. 
Flail prolapse can involve a single segment, multiple seg-
ments, one leaflet, or both leaflets (likely secondary to 
cordal rupture).
Both 2D TTE and TOE can be used to evaluate mitral 
valve morphology (Table 1). TOE will more reliably 
provide superior views across the LA window and should 
be considered in all cases of MVP assessment. The 
diagnosis of MVP using TTE should only be made in the 
parasternal long-axis view and/or the apical long-axis 
view as the hyperbolic paraboloid shape of the mitral 
valve annulus can give a false-positive diagnosis of MVP 
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(12). In addition, a description of the leaflet thickness or 
redundancy, annular dilatation and chordal length should 
be included. Visual accuracy of mitral valve shape and 
deformity may be improved using 3D echocardiography 
techniques, especially for anterior leaflet or commissural 
involvement (13, 14).
Doppler imaging is essential to determine the severity 
of MR. This should involve quantitative measures to 
determine disease progression, predict outcome and assess 
suitability for intervention. It is recommended that the 
colour flow Doppler area should not be used to quantify 
the severity of MR. Where feasible, the vena contracta 
or proximal isovelocity surface area should be used as a 
measure of severity (12). Both the pulsed Doppler mitral-
to-aortic time velocity–integral ratio and the systolic 
pulmonary flow reversal can be used as adjuncts to assist 
with quantifying the severity of MR (12).
The downstream effects of MR, including LA dilata-
tion, LV dilatation, LV dysfunction, pulmonary vein flow 
reversal, pulmonary hypertension, RV dilatation and 
 tricuspid regurgitation will also help determine the sever-
ity of MR. LV dilatation is a particularly important marker 
of progression in asymptomatic regurgitation, with moni-
toring of LV-end systolic diameter used to suggest when 
surgical intervention may be indicated.
Intraoperatively 2D TOE and/or 3D TOE is recom-
mended to assist surgical repair or replacement of the 
valve (14). Three-dimensional TOE has been shown to 
be more reliable than surgical inspection at accurately 
diagnosing the cleft-like indentations of the posterior 
mitral valve leaflet of myxomatous mitral valve dis-
ease and aiding repair (15). It is also important in per-
cutaneous methods of mitral valve repair such as with 
MitraClip (16).
Epidemiology
According to recent figures, the MVP prevalence is 1 – 2.4% 
(17, 18).  This is down from previous estimations of up to 35%. 
This difference can be explained by better understanding the 
anatomy of the mitral valve, stricter diagnostic criteria and 
better diagnostic technology. Nevertheless, MVP remains the 
most common cause of MR in developed countries.
Pathophysiology of MVP
Several pathological processes may cause prolapse of the 
mitral valve, including rheumatic heart disease, Marfan’s 
syndrome, endocarditis and myocardial ischemia, but 
degenerative MVP refers specifically to a specific spectrum 
of primary lesions (5, 19). On the two extremes of the 
spectrum are fibroelastic deficiency (FED) and Barlow’s 
disease. FED is a fibrillin deficiency leading to rupture of 
one of the chordae. In this case, the mitral valve leaflets 
are thinned and the annular size is normal (18, 20). At 
the other end of the spectrum is Barlow’s disease affect-
ing younger patients. The mitral annulus may become 
calcified and dilated with thickened leaflets secondary to 
myxomatous degeneration (19, 20).
Arrhythmias
Both supraventricular (SVA) and ventricular arrhythmias 
(VA) are associated with complications of MVP. This high 
incidence rate has been recognised for more than 20 years. 
A study in 1994 reported an incidence of SVA and VA asso-
ciated with MVP of 14 and 30%, respectively (21). When 
tested with continuous ECG monitoring, MVP patients 
had a prevalence of VA as high as 34% with premature ven-
tricular contractions as the most common pattern (66% of 
cases). Moderate-to-severe MR has been shown to be an 
independent risk factor to developing arrhythmias (22). 
Ikeda studied patients with idiopathic VT and found a high 
prevalence of MVP (12 out of 35 patients). VT originated 
from the LV in most of these cases in contrast to non-MVP 
(91.7 vs 69.6%) (23). Abnormal ventricular repolarisation, 
including early repolarisation, has also been linked to the 
presence of MVP (24, 25). A cross-sectional study of 100 
patients with MVP showed a high incidence of early repo-
larisation (represented by notch in the descending arm of 
QRS and J-point and/or ST segment changes) compared 
with healthy individuals without MVP (25).
Table 1 TOE and TTE views required for assessing the location of MVP.
View Segments viewed TOE TTE
1 A2 and P2, four-chamber view Sagittal view at 0° Parasternal long-axis view
2 A2 and P2 120°  
3 A1 and P1 As for 1 with angulation towards AV As for 1 with angulation towards AV
4 A3 and P3 As for 1 with angulation towards TV As for with angulation towards TV
5 P3, A2 and P1 (left to right, bi-commisural view) 40–60° Bicommisural view
6 A1, A2, A3, P1, P2 and P3 Transgastric view at 0° Parasternal short-axis view
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Left ventricular remodelling
The presence of a dilated left ventricle in the context of 
severe MR may indicate a period of LV remodelling. In 
acute primary MR, afterload may initially decrease due to 
the alternate pathway for ejection. However, with volume 
loading of the LV over time, the relatively thin-walled LV 
may dilate and hypertrophy. Consequently, the afterload 
in chronic compensated MR will be normal and elevated 
in chronic decompensated MR (26). Remodelling of the 
LV may allow MR to be tolerated with mild or no symp-
toms by increasing the stroke volume. However, pro-
gression to heart failure and possibly cardiac arrest can 
occur rapidly often in the presence of myocyte dysfunc-
tion and sympathetic activation (27). LV remodelling has 
been associated with evidence of VAs. However, there is a 
 paucity of  evidence assessing this link in the context of 
MVP without coronary artery disease (28).
Incidence of SCD
Despite the general impression of a benign course, 
 several case reports since the 1980s describe SCD in MVP 
patients, with a significant proportion of young and pre-
viously asymptomatic individuals (29, 30). A debate con-
tinues as to whether MVP is the cause of SCD or merely 
an association. Data from forensic autopsy examinations 
have reported floppy mitral valves in 5% of specimens 
(99 out of 2007 specimens). From those, MVP was con-
sidered directly responsible for the death of 17 patients 
(0.8% of cases) (31). This would rank MVP as the most 
common congenital and valvular cardiac cause of SCD. 
A consensus statement in 1997 from American and 
European societies does not attribute the cause of SCD to 
MVP, unless the prolapse is associated with valve redun-
dancy, thickening and regurgitation, QT prolongation or 
ST-T wave changes (32).
It is not known if the mitral valve repair or replace-
ment will have a preventive effect on VAs. Subsequently, 
the American Heart Association/European Society of 
Cardiology guidelines for VAs and SCD have no distinc-
tive recommendations for the management of VA or SCD 
in mitral valvular heart disease (33). Moreover, neither the 
recent American nor the European valvular heart disease 
guidelines mention a criterion for predicting or assuming 
SCD secondary to MVP (33, 34).
The 10-year mortality of asymptomatic MVP patients 
is reported to be 19%, with greater than moderate MR 
and impaired LV function as the most important risk 
factors (35). This draws similar comparisons to the 
all-cause mortality from MR with a flail leaflet (MR-FL). 
Collective data from the all-cause mortality from MR-FL 
showed an annual mortality of 1.8%. Not surprisingly, 
left ventricular ejection fraction and NYHA class were 
the risk factors for mortality. However, in the subgroup 
of patients with SCD, 40% of patients were categorised 
as NYHA class I (36). This highlights a subgroup of 
patients with SCD predominantly due to cardiac 
arrhythmia and not related to the severity of MR or LV 
failure in MVP. These patients were mostly young and 
asymptomatic. The subgroup of patients with NYHA 
class I had a yearly risk of SCD of 1% (36). This is equal 
to the overall mortality in hypertrophic obstructive 
cardiomyopathy (HCM, a pathology considered as one 
of the most common causes of SCD in young people 
(37). Consequently, it is logical to identify a high-
risk group of MVP similar to the recommendation for 
primary prevention in HCM.
Risk of SCD
As the incidence of SCD is very low in patients with 
MVP, studies have been directed towards identifying 
a high-risk subgroup that could benefit from primary 
or secondary prevention. Autopsy evaluation of SCD 
patients associated with MVP identified a subgroup of 
patients with isolated MVP. These patients were younger, 
mostly females and with less prevalence of MR (38). 
The high prevalence of MVP makes a strategy based 
on primary prevention feasible if the high-risk group 
could be strictly defined. Advances in echocardiography, 
cardiac magnetic resonance (CMR) and electrophysiology 
are promising in the identification of this group. 
Currently, no clear strategy is recommended for this 
small subgroup. Being young and asymptomatic makes 
it difficult to detect patients for primary prevention. 
However, we know that the incidence of SCD is much 
lower in young adults than in the general population 
(i.e. about 1:100,000). This incidence doubles if athletic 
(39). It is not known whether exercise increases the risk 
of SCD in MVP patients. Till now, MVP-associated SCD 
has been categorised as idiopathic VF. The real question 
is whether it is possible to prospectively identify risk 
factors for SCD in individuals with MVP.
A retrospective American study identified 12 out of 50 
SCD patients with idiopathic VF as having MVP. A quarter 
of MVP patients had a family history of SCD (40). Another 
study by Vohra and coworkers in 1993 prospectively 
studied seven patients with MVP associated with mild MR 
and normal LV function. All patients initially presented 
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with syncope or OOHCA and the mean follow-up 
period was 2.5 years. They had proven VAs on Holter or 
electrophysiological study (EPS). Patients were treated 
with anti-arrhythmic pharmacotherapy, although with 
limited efficacy as there were two who suffered sudden 
death. Two patients underwent reparative surgery, but the 
arrhythmias were re-inducible on repeat EPS (41). This is 
in contrast to another study in which surgical correction 
had a protective effect (36).
Prevention of SCD
A cohort study that reviewed 24 patients who had 
idiopathic VF/VT OOHCA found echocardiographic 
evidence of bileaflet MVP in 10 patients (42%). The author 
named it malignant bileaflet MVP. Those patients with 
MVP had higher incidence of ECG abnormalities and VAs 
(42). Electrolyte disturbances can be an aggravating factor 
contributing to the occurrence of VAs and subsequently 
SCD (43). Screening programmes, technical availability 
(ECG, echocardiography) and cost remain obstacles for 
a wide application of primary prevention. Nevertheless, 
if MVP had been detected accidentally or in a screening 
program (e.g. athletes or relatives of patients with SCD), it 
may be easier to reconsider recommending a strategy for 
those patients depending on clear risk criteria. However, an 
implantable cardiac defibrillator (ICD) is not without risk, 
especially for young people. EPS, MRI and echocardiography 
may be helpful in identifying the right group.
Secondary prevention is an easier question. In patients 
diagnosed with idiopathic VF, ICD is a class I recommen-
dation for survivors (44). A follow-up of 24 patients with 
OOHCA with VF/VT showed patients with bileaflet MVP 
had a significantly better ICD appropriateness compared 
with non-MVP patients (80 vs 36%, P = 0.04). However, 
this may had been affected by a longer follow-up period 
in the MVP group (42).
Cardiac magnetic resonance imaging
The advent of CMR has shed further light on this condi-
tion. CMR has shown an association between MVP and 
papillary muscle fibrosis. In a study of 16 patients, 8 had 
a history of VA on previous Holter monitoring (couples of 
VPCs or non-sustained VT) and 63% of the MVP patients 
had papillary muscle fibrosis on late gadolinium enhance-
ment (45). Basal LV hypertrophy is another abnormality, 
which can be better detected by CMR in such patients. 
However, its significance in cases of arrhythmias and SCD 
remains unknown (46).
Other causes of SCD with MVP
It should be noted that other possible mechanisms of 
cardiac arrest should not be ignored. Primary spontaneous 
chordal rupture is one of the recognised complications 
of MVP. This may cause acute MR and cardiogenic 
pulmonary oedema (47). Intramyocardial small vessel 
disease has a known association with SCD (48). One of 
its variants, fibromuscular dysplasia, had been observed 
by pathologic examination more frequently in MVP than 
in the controls (75 vs 25%). This variant of small vessel 
disease in MVP cases was associated with fibrosis of the 
basal interventricular septum (49).
Conclusion
In this case, the patient was previously asymptomatic 
and presented with an aborted SCD. Severe MR was 
demonstrated with echocardiography. The presence of 
a dilated LV at presentation and later on during CMR 
suggests chronic severe MR with extensive LV remodelling 
in the absence of symptoms. It is possible that the 
haemodynamic effects of the acute regurgitation may have 
caused syncope, which progressed to dysrhythmia and 
cardiac arrest due to reduced coronary flow. It is equally 
possible that there was a primary dysrhythmia associated 
with MVP or left ventricular remodelling. Early TOE and 
CMR are important, as is a greater understanding of the 
possible electrophysiological mechanisms of primary 
arrhythmogenesis.
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